Please login to the form below

Not currently logged in
Email:
Password:

VentiRx appoints James Kyle Bryan as chief medical officer

He has more than 20 years of experience in oncology

US-based biopharma VentiRx Pharmaceuticals has appointed Dr James Kyle Bryan as chief medical officer.

Dr Bryan joins from Seattle Genetics, where he served as VP, medical affairs and before that as VP of global product development.

During his career, Dr Bryan has focused on drug discovery in oncology, and has a medical background in haematology and oncology.

This experience will benefit VentiRx as it prepares to advance the development of VTX-2337 for patients with ovarian cancer and head and neck cancer.

“His extensive experience in oncology drug development combined with his strong connections to oncology thought leaders will be invaluable to VentiRx going forward,” said Dr Robert Hershberg, CEO of VentiRx. “We are delighted to have him join the VentiRx team.”

30th April 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics